In virtue of this, this systematic review aims to study the current evidence and knowledge on the pathophysiologic mechanisms of GH and IGF-1 in the development of NASH and assess the potential benefits of GH and IGF-1 therapy in this patient population. Here, GH1 is linked to metabolic dysfunction-associated steatohepatitis.